Phase I trial with carboplatin and RAD001 in metastatic breast cancer

被引：0
|
作者：
Eucker, J.
Schwarzlose-Schwarck, S.
Martus, P.
Regierer, A. C.
Schulz, C. O.
Liu, H.
Scholz, C. W.
Schefe, J. H.
Possinger, K.
机构：
[1] Charite, Dept Hematol & Oncol, Berlin, Germany
[2] Charite, Inst Biostat & Clin Epidemiol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11554
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC)
    Gross, M. E.
    Soscia, J.
    Sakowsky, S.
    Castellanos, O.
    Agus, D. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] PHASE-3 RANDOMISED TRIAL OF EVEROLIMUS (RAD001) VS PLACEBO IN METASTATIC RENAL CELL CARCINOMA
    Escudier, B.
    Ravaud, A.
    Oudard, S.
    Hutson, T. E.
    Porta, C.
    Bracarda, S.
    Gruenwald, V.
    Thompson, J.
    Figlin, R. A.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 45 - 45
  • [43] Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
    Andre, F.
    Campone, M.
    Hurvitz, S. A.
    Vittori, L.
    Pylvaenaeinen, I.
    Sahmoud, T.
    O'Regan, R. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial
    Hurvitz, S.
    O'Regan, R.
    Campone, M.
    Manlius, C.
    Vittori, L.
    Mukhopadhyay, P.
    Massacesi, C.
    Sahmoud, T.
    Naughton, M.
    Andre, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 267 - 267
  • [45] Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results
    Muro, K.
    Boku, N.
    Yamada, Y.
    Nishina, T.
    Doi, T.
    Takiuchi, H.
    Tajima, T.
    Takahashi, A.
    Fujita, Y.
    Ohtsu, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab
    Cardoso, F.
    Gianni, L.
    Jerusalem, G.
    Fasolo, A.
    Bergh, J.
    Dieras, V.
    Manlius, C.
    Mukhopadhyay, P.
    Massacesi, C.
    Sahmoud, T.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 261 - 261
  • [47] Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial
    Azria, David
    Rebillard, Xavier
    Coux, Nathalie
    Jarlier, Marta
    Thuret, Rodolphe
    Llacer-Moscardo, Carmen
    Charissoux, Marie
    Culine, Stephane
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [48] Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer.
    Abida, Wassim
    Milowsky, Matthew I.
    Ostrovnaya, Irina
    Gerst, Scott R.
    Rosenberg, Jonathan E.
    Regazzi, Ashley Marie
    McCoy, Asia S.
    Boyd, Mariel Elena
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
    Awada, Ahmad
    Cardoso, Fatima
    Fontaine, Christel
    Dirix, Luc
    De Greve, Jacques
    Sotiriou, Christos
    Steinseifer, Jutta
    Wouters, Carine
    Tanaka, Chiaki
    Zoellner, Ulrike
    Tang, Pui
    Piccart, Martine
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
  • [50] RAD001: Phase II Trial in Relapsed/Refractory Waldenstrom Macroglobulinemia, the DFCI Experience
    Ghobrial, I. M.
    Roccaro, A. M.
    Chuma, S.
    Sam, A. P.
    Leduc, R.
    Nelson, M.
    O'Connor, K.
    Harris, B.
    Soumerai, J.
    Warren, D.
    Jacobsen, E.
    DeAngelo, D.
    Berg, W.
    Anderson, K. C.
    Richardson, P. G.
    Witzig, T. E.
    Treon, S. P.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S82 - S83
12345